Melody Chang, RPh, BCOP, MBA, is the Director of Pharmacy Operations of Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, with over 230 physicians, 200 nurse practitioners and physician assistants and nearly 100 locations in the state of Florida. In addition, she is also the Director of Pharmacy Operations of American Oncology Network, a fastest growing oncology network represents more than 90 physicians, 50 advanced practice providers practicing at 50 locations across 15 states.
In her role, she oversees pharmacy operations, establishes guidelines and standard operating procedures, develops drug utilization and formulary initiatives that ensured the cost-effectiveness and optimized therapeutic outcomes.
Melody Chang has over 20 years of clinical and management experience in pharmacy. Prior to joining FCS, Melody worked as a lead pediatric oncology pharmacist at Lee Health in Fort Myers, FL. She worked as a oncology pharmacist at MD Anderson in Orlando, FL. (now is Orlando Health UF Health Cancer Center)
Melody received her B.S. in Pharmacy from China Medical University in Taiwan and earned her MBA degree from Tulane University in New Orleans. She is a Board-Certified Oncology Pharmacist. She has served as Pharmacist Liaison to the Florida Society of Clinical Oncology (FLASCO) Board of Directors since 2017.
As the biosimilar market rapidly expands, there are still hurdles that hinder the uptake. The lack of knowledge and confidence regarding biosimilars among healthcare providers and patients continue to serve as a barrier to adoption.
Giving the example of successful educational effort in a national community oncology network, this presentation will help participants learn how to identify and to address the knowledge gaps. It also gives tips on how to disseminate useful information to stakeholders (providers, patients, and payers) via different messaging tools across various platforms
Giving the successful biosimilars uptake in a large national community oncology network, this presentation will help participants learn 3 things:
1. Key tips for successful biosimilars implementation within a dynamic market
2. Economic impact to payers, patients, and providers
3. What to expect for the future development